SEC Form 4 · accession 0000711377-16-000074
NEOGEN CORP · NEOG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard T Crowder
Director
Period of report
May 19, 2016
Accepted (ET)
May 23, 2016 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000711377
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| common Stock | May 19, 2016 | M | 11,250 | $13.5555 | A | 12,750 | D | |
| Common Stock | May 19, 2016 | M | 3,000 | $22.42 | A | 20,250 | D | |
| Common Stock | May 19, 2016 | M | 4,500 | $22.7533 | A | 24,750 | D | |
| common Stock | May 19, 2016 | M | 4,500 | $28.6666 | A | 24,750 | D | |
| Common Stock | May 19, 2016 | M | 3,000 | $41.6533 | A | 27,750 | D | |
| Common Stock | May 19, 2016 | M | 1,000 | $41.26 | A | 28,750 | D | |
| common Stock | May 19, 2016 | S | 27,250 | $48.0477 | D | 1,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| common Stock (Right to Buy) | $13.5555 | May 19, 2016 | M | 11,250 | D | Oct 9, 2012 | Oct 9, 2019 | Common Stock | 11,250 | 16,000 | D |
| Common Stock (Right to Buy) | $22.42 | May 19, 2016 | M | 3,000 | D | Oct 7, 2013 | Oct 7, 2020 | Common Stock | 3,000 | 13,000 | D |
| Common Stock (Right to Buy) | $22.7533 | May 19, 2016 | M | 4,500 | D | Oct 6, 2014 | Oct 6, 2024 | Common stock | 4,500 | 8,500 | D |
| Common Stock (Right to Buy) | $28.6666 | May 19, 2016 | M | 4,500 | D | Oct 5, 2015 | Oct 4, 2022 | Common Stock | 4,500 | 4,000 | D |
| Common Stock (Right to Buy) | $41.6533 | May 19, 2016 | M | 3,000 | D | Oct 3, 2015 | Oct 3, 2023 | Common Stock | 3,000 | 1,000 | D |
| Common Stock (Right to Buy) | $41.26 | May 19, 2016 | M | 1,000 | D | Oct 2, 2015 | Oct 2, 2024 | Common Stock | 1,000 | 0 | D |
Remarks
Dr. Crowder resigned as a Director of the Company, effective April 30, 2016. The options granted above had ten year lives, and one third of the total grant was vested each year on the anniversary date of the grant.